New research from Charles Rivers Associates for EFPIA demonstrates that a voucher system designed to drive research and development (R&D) into new antibiotics would cost Member States 45% less than previously estimated by the European Commission.

Antimicrobial resistance (AMR) is one of the world’s most pressing health emergencies.Yet despite the urgent need, private investment in antimicrobial R&D is limited. To prevent bacteria developing resistance to existing treatments, the aim with any new antibiotic is to use it as little as possible - not an attractive proposition for investors.

The transferable exclusivity voucher (TEV) is designed to address this challenge by rewarding the discovery of novel antibiotics without requiring upfront public investment. 

 

Read more